menu ☰
menu ˟

Flibanserin to treat hypoactive sexual desire disorder in premenopause goes back to FDA

17 Feb 2015
Sprout Pharmaceuticals has resubmitted a new drug application to the FDA for flibanserin, an investigational therapy to treat hypoactive sexual desire disorder in women during premenopause, according to a news release from the company. After receivin...

Click here to view the full article which appeared in Psychiatry

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.